Predictive model identified women at excess risk for poor outcomes.
Foretelling which women with preeclampsia will develop fatal or life-threatening complications has proven difficult. To develop a predictive model, investigators followed 2023 women in Canada, Australia, New Zealand, and the U.K. who were admitted to tertiary care hospitals with preeclampsia or who developed preeclampsia after admission. Potential predictors of poor outcomes included variables encompassing demographics, medical and obstetric histories, and clinical and laboratory findings.
A total of 261 women experienced adverse outcomes, for which six variables (gestational age, chest pain or dyspnea, serum creatinine level, platelet count, aspartate aminotransaminase level, and oxygen saturation) were predictive. The model predicted adver…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)